I.CERAM SA (FR:ALICR) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
I.CERAM SA has announced a pilot clinical study in Paris to evaluate the benefits of its innovative antibiotic-loaded Porous Ceramic Sternal Stabilisation Implant, designed to improve chest wall stability and prevent infections after cardiac surgery. This implant aims to reduce complications and costs associated with post-operative mediastinitis, a serious condition affecting patients worldwide. The study, conducted in collaboration with renowned cardiac surgeon Professor Pascal Leprince, will test the implant’s effectiveness on 10 patients.
For further insights into FR:ALICR stock, check out TipRanks’ Stock Analysis page.